

# ESMO Advanced Course on Biomarkers for Precision Medicine

## Programme

**ZURICH**  
SWITZERLAND

**12-13 NOVEMBER 2021**

**Co-Chairs**

Federica Di Nicolantonio, Italy  
Jorge Reis-Filho, United States

# ESMO ADVANCED COURSE PROGRAMME BIOMARKERS FOR PRECISION MEDICINE

Zurich, Switzerland  
12-13 November 2021

**CO-CHAIRS:** Federica Di Nicolantonio, Italy  
Jorge Reis-Filho, United States

**SPEAKERS:** Fabrice André, France  
Francois Clément Bidard, France  
Christine Desmedt, Belgium  
Elena Elez, Spain  
Ellen Heitzer, Austria  
Caterina Marchiò, Italy  
Joaquin Mateo, Spain  
Clare Turnbull, United Kingdom

## LEARNING OBJECTIVES

- To recognize the different modalities of molecular assays needed for contemporary practice of precision oncology.
- To determine the different technologies available for biomarker testing and the context where these technologies are most effective, depending on the nature of the biomarker and the availability of biological samples.
- To comprehend the different modalities of cfDNA testing and their applications in disease monitoring, development of resistance and minimal residual disease assessment.
- To recognize the applications of multiplex immunophenotyping, spatial transcriptomics and artificial intelligence applied to tissue samples.
- To define the contribution of multidisciplinary teams and tumour boards for therapy decision making.

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

**illumina**<sup>®</sup>



## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 12 November 2021

---

09:00-09:10	<b>Welcome and introduction</b>
10'	Welcome and Learning Objectives Introduction, Federica Di Nicolantonio, IT and Jorge Reis-Filho, USA
09:10-10:40	<b>Session 1 – New technologies for precision medicine</b>
25'	Single cell analyses in cancer, Christine Desmedt, BE
5'	Discussion
25'	Multiplexed immunophenotyping and transcriptomics, Caterina Marchiò, IT
5'	Discussion
25'	AI in pathology, Jorge Reis-Filho, USA
5'	Discussion
10:40-11:10	<i>Coffee break</i>
11:10-12:10	<b>Session 2 – NGS comes to the clinic</b>
25'	NGS in oncology, Fabrice André, FR
5'	Discussion
25'	Technologies for the analysis of circulating DNA, Ellen Heitzer, AT
5'	Discussion
12:10-13:10	<i>Lunch</i>
13:10-15:10	<b>Session 3 – Clinical implementation of NGS</b>
25'	Organization and role of the Molecular Tumour Board, Elena Elez, ES
5'	Discussion
25'	ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Joaquin Mateo, ES
5'	Discussion
25'	What else can you get from NGS beyond tumour mutations? Jorge Reis-Filho, USA
5'	Discussion
25'	Germline genetics for clinical decision making, Clare Turnbull, UK
5'	Discussion
15:10-15:40	<i>Coffee break</i>
15:40-17:00	<b>Session 4 – Biomarkers for Immune checkpoint inhibitors</b>
30'	Current biomarkers for immuno-oncology: what is the state of the art? Caterina Marchiò, IT
5'	Discussion
35'	Emerging biomarkers for immuno-oncology and immuno-surveillance, Christine Desmedt, BE
10'	Discussion
19:00	<i>Networking dinner</i>

## Saturday, 13 November 2021

---

09:00-12:30

### **Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

### **Workshop 1**

How to translate comprehensive genomic profiling into clinical decision?

Fabrice André, FR

### **Workshop 2**

Tailoring the liquid biopsy assay to your patient

Francois Clement Bidard, FR

### **Workshop 3**

How to develop a molecularly guided precision oncology trial?

Federica Di Nicolantonio, IT

11:00-11:30

*Coffee break*

11:30-12:30

### **Workshops continuation**

12:30-13:00

### **Feedback on the workshops from each group**

13:00-13:15

### **Synthesis and wrap-up**

13:15-14:15

*Lunch*